Kimberly-Clark acquires J&J’s spinout Kenvue for $48.7bn, creating a conglomerate with $32bn in annual revenue. Shareholders to receive $3.50 per share and 0.14625 Kimberly-Clark shares per Kenvue share. Deal expected to close in the second half of 2026, with Kimberly-Clark owning 54% and Kenvue shareholders 46% of the combined company.

Kenvue, known for Tylenol, faces controversy over safety concerns linked to autism. FDA updated Tylenol label in Sept 2025, warning pregnant women of risks. Kenvue filed petition against claims. Besides Tylenol, Kenvue produces Band-Aid, Zyrtec, Benadryl, Neutrogena, and Aveeno. Kimberly-Clark emphasizes complementary product portfolio beyond Tylenol.

Kimberly-Clark CEO assures thorough review of the transaction, highlighting strategic, not opportunistic, decision-making process. Deal marks significant M&A activity in the pharmaceutical industry.

Read more at Yahoo Finance: Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn